Search Results
Your search for Blood matches 4627 pages
Showing 1551 - 1600Anticipate Difficulties by Patients in Adhering to Tamoxifen Therapy
Patients prescribed tamoxifen may not report when they interrupt or discontinue therapy, according to the results of a study published in the Journal of Clinical Oncology.1 Using blood draws to determine serum levels of tamoxifen among 1,177 premenopausal women with invasive breast cancer, the...
One in Six Premenopausal Women With Invasive Breast Cancer Is Nonadherent to Tamoxifen Therapy
Measuring serum levels of tamoxifen among premenopausal women being treated for invasive breast cancer identified a “worryingly high proportion of patients, one in six, who were nonadherent to therapy at only 1 year after treatment prescription,” researchers reported in the Journal of Clinical...
Tumeur Fibro-Plastique
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Association of Community Cancer Centers Announces 2020 Innovator Award Recipients
The Association of Community Cancer Centers (ACCC) announced the winning programs for its 10th annual ACCC Innovator Awards, highlighting the year’s leading-edge strategies to challenges faced by oncology programs and practices across the country. The eight ACCC Innovator Award winners feature...
How to Treat Patients With Multiple Myeloma Cost-Effectively Without Compromising Outcome
The dramatic advances in the diagnosis and treatment of multiple myeloma over the past 20 years have resulted in significant improvements in overall survival, with 5-year relative survival rates now around 50% and more than 60% for patients younger than age 70.1 The proteasome inhibitors...
How the First International Summit on Interventional Pharmacoeconomics Is Sparking Discussion on Reducing Cancer Costs
Three years ago, former Chief Executive Officer of ASCO, Allen S. Lichter, MD, Laurence H. Baker, DO, Professor in the Departments of Internal Medicine and Pharmacology at the University of Michigan Medical School in Ann Arbor; Leonard Saltz, MD, a gastrointestinal oncologist at Memorial Sloan...
Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL
The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the tre atment of chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on studies where...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib, Pemmaraju, and Medeiros highlight the clinically aggressive blastic plasmacytoid dendritic cell neoplasm. For each quiz...
Tafasitamab-cxix in the Treatment of Diffuse Large B-Cell Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On July 31, 2020, tafasitamab-cxix, a CD19-directed...
Chemotherapy-Free Approaches in Follicular and Mantle Cell Lymphomas
As chemotherapy and chemoimmunotherapy regimens reach their maximal impact in follicular lymphoma and mantle cell lymphoma, clinicians are turning to chemotherapy-free approaches to achieve better control, less toxicity, and (hopefully) a cure. During the ASCO20 Virtual Education Program, Sonali M. ...
Pet Therapy: How the Cat I Never Wanted Saved My Life
My husband and I adopted our cat, Franklin, on a cold November day. It was one of the last days Andrew felt well enough to leave the house to go anywhere other than to chemotherapy or a doctor’s appointment. Our news at these appointments had shifted toward the negative, with disease progression...
Rucaparib in Metastatic Castration-Resistant Prostate Cancer With Deleterious BRCA Alterations
As reported in the Journal of Clinical Oncology by Abida and colleagues, the phase II TRITON2 trial has shown that rucaparib produces durable responses in patients with metastatic castration-resistant prostate cancer with deleterious BRCA1 or BRCA2 alterations. The trial supported the May 2020...
FDA Pipeline: Approval for First Liquid Biopsy Next-Generation Sequencing Companion Diagnostic; Designations in Ovarian Cancer, Leukemia, and Lymphoma
Recently, the U.S. Food and Drug Administration (FDA) approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing technology to identify patients with non–small cell lung cancer (NSCLC) and specific types of EGFR mutations. The FDA also granted Fast Track...
Nonmetastatic Castration-Resistant Prostate Cancer
Nonmetastatic castration-resistant prostate cancer arises in the subset of men with biochemically recurrent disease (ie, rising prostate-specific antigen [PSA] level after definitive therapy in the absence of metastases) who develop PSA progression after chronic exposure to androgen-deprivation...
Phase III Study of AR Antagonist in Nonmetastatic Castration-Resistant Prostate Cancer
In the phase III ARAMIS trial reported in The New England Journal of Medicine,1 Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Universite Paris-Sud, Villejuif, France, and colleagues found that the androgen-receptor (AR) antagonist darolutamide significantly prolonged metastasis-free...
ASH Releases New Clinical Practice Guidelines on the Treatment of Older Adults With Newly Diagnosed Acute Myeloid Leukemia
The American Society of Hematology (ASH) has published new guidelines to help older adults with acute myeloid leukemia (AML) and their health-care providers make critical care decisions, including if and how to proceed with cancer treatment and the need for blood transfusions for those in hospice...
New Effort to Address Health Disparities for Black Men
The Prostate Cancer Foundation and Robert F. Smith, Founder, Chairman and Chief Executive Officer (CEO) of Vista Equity Partners, have announced a new effort to reduce deaths from prostate cancer, one of the largest health disparities facing Black men today. “As African American men are at an...
Cleveland Clinic Cancer Center Oncologists Earn National Recognition as Institution Expands Staff
Cleveland Clinic Cancer Center recently announced news about the following physicians, including the appointment of four new staff members: Shilpa Gupta, MD, received a 2-year, $573,850 grant from the Department of Defense to study biomarkers of response and resistance to immunotherapy and to apply ...
Flossie Wong-Staal, PhD, Molecular Biologist Who Uncovered the Secrets of Human Immunodeficiency Virus, Dies at 73
The origin of the human immunodeficiency virus (HIV) has been traced back to Kinshasa, in the Democratic Republic of Congo, around 1920, when the virus crossed species from chimpanzees to humans. It wasn’t until the 1980s that epidemiologic data began to sum up the number of people who were...
A Pioneering Neurosurgeon Shares Hard-Earned Wisdom Gained Along the Road From the Segregated South
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with noted neurosurgeon Keith L. Black, MD, Chair of Cedars-Sinai Medical Center’s Department of Neurosurgery and Director of the Maxine Dunitz Neurosurgical Institute. During his career, Dr. Black has...
Selinexor in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
On June 22, 2020, the oral nuclear export inhibitor selinexor was granted accelerated approval for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic...
Dr. Jimmie C. Holland’s Research Has Long Underscored the Importance of Caring for the Whole Patient
Jimmie C. Holland, MD, who served as the inaugural Chairman of the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering Cancer Center, died on December 24, 2017, at the age of 89. The ASCO Post paid tribute to Dr. Holland in its January 25, 2018, issue. Here, as part of our ...
Highlights of Research in Lymphomas Presented During the EHA25 Virtual Congress
To complement The ASCO Post’s continued coverage of the virtual edition of the 25th European Hematology Association Annual Congress (EHA25 Virtual), here are a few abstracts selected from the meeting proceedings focusing on clinical research in Hodgkin and marginal zone lymphomas. Omission of...
Tazemetostat for Adults With Relapsed or Refractory Follicular Lymphoma
On June 18, 2020, the EZH2 inhibitor tazemetostat was granted accelerated approval for the treatment of adults with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test, and who have...
NCCN Clinical Practice Guidelines in Oncology: 2020 Updates
In 1996, the National Comprehensive Cancer Network (NCCN) published its first set of Clinical Practice Guidelines in Oncology®, covering eight tumor types. Guidelines are now published for more than 60 tumor types and topics. During the NCCN’s 25th Annual Conference, which was held virtually during ...
Lost in Translation: A Fisherman’s Tale
The ASCO Post is pleased to reproduce installments of the Art of Oncology, as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Higher Prevalence of Germline Mutations Identified in Young Adults With Cancer
A new study has found that a higher-than-expected proportion of young adults with cancer harbor genetic germline mutations that have implications for treatment, surveillance, and other family members who may be at risk. Patients with “early-onset cancers”—cancers that typically do not occur in...
Expert Point of View: David Sallman, MD
David Sallman, MD, an assistant member of the Malignant Hematology Department of Moffitt Cancer Center and Research Institute, Tampa, Florida, commented on the IMerge and QUAZAR studies for The ASCO Post. As background, he noted the “predominant struggle” of patients with lower-risk myelodysplastic ...
Novel Treatments Emerge for Patients With Lower-Risk Myelodysplastic Syndromes
Patients with lower-risk myelodysplastic syndromes (MDS) who are dependent on red blood cell transfusions have limited options, especially if they are no longer responding to erythropoiesis-stimulating agents. Research presented during the virtual edition of the 25th European Hematology Association ...
Incorporating Immunotherapy Into Treatment of Early-Stage NSCLC
There is a strong rationale for incorporating immunotherapy into the treatment of early-stage non–small cell lung cancer (NSCLC), given the breakthrough results with PD-1 checkpoint inhibitors as monotherapy, combined with immunotherapy, or combined with chemotherapy in advanced-stage NSCLC. As...
FDA Pipeline: Designations in Kidney and Lung Cancers, Myelodysplastic Syndromes, and More
Over the past few weeks, the U.S. Food and Drug Administration (FDA) has issued designations and accepted applications for novel agents, as well as approved companion diagnostics. We summarize these regulatory movements below. Breakthrough Therapy Designation for MK-6482 in von Hippel-Lindau...
Risk of Breast Cancer After Total-Body Irradiation and Blood or Marrow Transplantation for Hematologic Malignancies
In an analysis from the Blood or Marrow Transplantation Survivor Study reported in the Journal of Clinical Oncology, McDonald et al found that total-body irradiation in women undergoing autologous or allogeneic blood or marrow transplantation for hematologic malignancies was associated with an...
Updated ASCO Guideline Revisits Evidence on Prevention and Treatment of Chemotherapy-Induced Neuropathy
Peripheral neuropathy is one of the most prominent chronic side effects of chemotherapy and can linger for years, causing discomfort as well as impaired functionality and quality of life. Yet oncologists have struggled to identify definitive treatment and prevention strategies. In an effort to help ...
Outcomes With PET-Directed Therapy for Limited-Stage DLBCL
As reported in the Journal of Clinical Oncology by Daniel O. Persky, MD, and colleagues, the phase II Intergroup National Clinical Trials Network Study S1001 has shown good outcomes with positron-emission tomography (PET)-directed therapy in patients with limited-stage diffuse large B-cell lymphoma ...
Pevonedistat Plus Azacitidine May Be of Benefit in Higher-Risk Myelodysplastic Syndromes
In higher-risk myelodysplastic syndromes (MDS), a global phase II open-label study found that the combination of pevonedistat plus azacitidine was associated with a trend toward improved event-free survival and numerically longer overall survival, as compared with azacitidine alone, according to...
The Wake
The ASCO Post is pleased to reproduce installments of the “Art of Oncology,” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Prominent Surgeon and Teacher LaSalle D. Leffall, Jr, MD, Promotes Hard Work and Education to Overcome Boundaries
LaSalle D. Leffall, Jr, MD, the Charles R. Drew Professor of Surgery at Howard University College of Medicine in Washington, DC, died on May 25, 2019, at the age of 89. The ASCO Post paid tribute to Dr. Leffall in its July 10, 2019, issue. Here, as part of our 10-Year Anniversary Series, we...
Lurbinectedin in Previously Treated Metastatic Small Cell Lung Cancer
On June 15, 2020, the alkylating drug lurbinectedin was granted accelerated approval for treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression during or after platinum-based chemotherapy.1,2 Supporting Efficacy Data Accelerated approval was based on...
Role of Rituximab in the Treatment of Children and Adolescents With Mature B-Cell Non-Hodgkin Lymphoma
Minard-Colin et al recently reported for the European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group (EICNHL/COG) a significant improvement in event-free survival among children and adolescents (aged 6 months to 18 years) with high-risk mature B-cell non-Hodgkin lymphoma...
Blood Cancer Discoveries Program Names Grant Recipients
The Leukemia & Lymphoma Society, the Mark Foundation for Cancer Research, and the Paul G. Allen Frontiers Group recently announced the awarding of more than $6.75 million to nine scientists. Each project will be supported by an award of $750,000 over a 3-year period. Grant Recipients The Blood ...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros highlight the rare primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS). For each ...
Expert Point of View: Komal Jhaveri, MD
“Surprisingly, the phase II PARSIFAL trial did not show a statistical superiority in progression-free survival for fulvestrant plus palbociclib over letrozole plus palbociclib in the first-line treatment of patients with endocrine-sensitive, metastatic breast cancer. The noninferiority hypothesis...
In Case You Missed It: Quick Takes on Novel Therapies for Solid and Hematologic Malignancies
Because of the COVID-19 pandemic, oncology providers from around the world had to forgo their annual trip to McCormick Place—but the show did go on. We all realized important research can still be presented, clinicians and fellow researchers will still listen, and ASCO presentations will still...
Expert Point of View: John D. Minna, MD
John D. Minna, MD, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research at The University of Texas Southwestern Medical Center, Dallas, was enthusiastic about this approach. “When I first heard about it, I was so...
Can Radiomics Predict Survival in Patients With NSCLC Receiving Immunotherapy?
Immunotherapy with immune checkpoint inhibitors has made great strides in the treatment of many cancers, but only between 25% and 50% of patients respond with clinical benefit, and these agents come with adverse events and high price tags. Thus, preselection of patients who are likely to respond to ...
In Keynote Lecture, Anthony Fauci, MD, Explores What We Know About COVID-19 and What’s Being Done to Combat It
Kicking off the American Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer earlier this week, Anthony Fauci, MD, gave the keynote lecture, “Coronavirus Infections: More Than Just the Common Cold.” As Dr. Fauci told listeners, “[COVID-19]—and other infectious...
Expert Point of View: Alice Mims, MD
Alice Mims, MD, Associate Professor of Hematology at The Ohio State University Comprehensive Cancer Center–The James, shared her insights on the VIALE-A study. “The results of the VIALE-A study have been highly anticipated and are exciting, given the improvement seen in both overall survival and...
VIALE-A Trial Supports Survival Benefit of Venetoclax Plus Azacitidine in Elderly Patients With AML
In the phase III VIALE-A trial, venetoclax added to azacitidine led to a significant and clinically meaningful improvement in response rates and overall survival, as compared with azacitidine alone, in treatment-naive predominantly elderly patients with acute myeloid leukemia (AML) ineligible for...
Study Identifies Factors That May Predict Toxicities in Patients Treated With CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has proved to be a valuable treatment option for patients with lymphoma in whom other therapies have failed. In clinical trials, the cellular immunotherapy was shown to provide durable remissions for nearly 40% of patients with large B-cell lymphoma....
Effectiveness of Routine Blood Testing in Detection of Disease During Active Surveillance for Indolent Non-Hodgkin Lymphoma
In an Australian study reported in JCO Oncology Practice, Piercey et al found that routine blood tests have little utility in detecting relapse or progression of disease during active surveillance of patients with indolent non-Hodgkin lymphoma. As stated by the investigators, “Patients with...
